The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy
> From 1996 to 2001, Purdue conducted more than 40 national pain-management and speaker-training conferences at resorts in Florida, Arizona, and California. More than 5000 physicians, pharmacists, and nurses attended these all-expenses-paid symposia, where they were recruited and trained for Purdue's national speaker bureau.
> One of the cornerstones of Purdue's marketing plan was the use of sophisticated marketing data to influence physicians’ prescribing.
> Purdue “aggressively” promoted the use of opioids for use in the “non-malignant pain market.” A much larger market than that for cancer-related pain, the non–cancer-related pain market constituted 86% of the total opioid market in 1999. Purdue's promotion of OxyContin for the treatment of non–cancer-related pain contributed to a nearly tenfold increase in OxyContin prescriptions
> A consistent feature in the promotion and marketing of OxyContin was a systematic effort to minimize the risk